Protalix BioTherapeutics Inc. recently released a corporate presentation highlighting its strategic initiatives and commercial portfolio in the rare disease space. The presentation provides an overview of their established commercial foundation, which supports further expansion efforts. Among the key products mentioned is Elelyso® (alfataliglicerase in Brazil), an FDA-approved treatment that is commercially marketed. The presentation also discusses the commercialization aspects of Elfabrio® (pegunigalsidase alfa-iwxj), a product approved for the treatment of adult patients with Fabry disease. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.